INO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Inovio Pharmaceuticals Inc (INO) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock lacks significant positive catalysts, has weak technical indicators, and faces legal challenges. While there is potential for long-term growth due to partnerships and upcoming trials, the current financial performance and sentiment do not support an immediate investment.
The MACD is negative and expanding downward, indicating bearish momentum. RSI is neutral at 39.893, showing no clear trend. Moving averages are converging, and the stock is trading near its support level of 1.665, with resistance at 1.814. Overall, the technical indicators suggest a lack of strong upward momentum.
The partnership with Akeso to advance a novel combination treatment for glioblastoma (GBM) and the anticipated dosing trial in the second half of 2026 could provide long-term growth opportunities.
Class action lawsuits alleging misleading information about the CELLECTRA device could negatively impact investor sentiment. Additionally, the company's financial performance remains weak, with negative net income and declining EPS.
In Q3 2025, revenue remained at 0 with no YoY growth. Net income improved by 80.79% YoY but remains negative at -$45.5M. EPS dropped by 2.25% YoY to -0.87. Gross margin is 100%, but this is not indicative of profitability given the lack of revenue.
No specific analyst rating or price target changes provided. Wall Street sentiment appears neutral, with no significant hedge fund or insider trading activity.
